Home / Intelligence / White Papers / Spending Wisely in Europe
By 2022 Europe is forecast to account for 20% of a global US$1.2 trillion pharmaceutical market. For executives from emerging biopharmaceutical companies planning to develop and commercialize their assets in Europe, the views of biopharmaceutical investors are critical, as investors provide the necessary investments. Additionally, investors who have analyzed numerous biopharmaceutical companies will have valuable experience on what drives commercial success.
In this paper, we aim to understand the views of both investors and biopharmaceutical companies, specifically on the investments into, and timings of, pre-commercial activities. We surveyed 42 senior stakeholders in director-level roles or higher from both biopharmaceutical companies and investment firms, including private equity, venture capital, investment banking, and business development and licensing (BD&L).
Authors
Alexander Fink, Jackson Carroll, Dr. Tony Xu, Herman Sanchez
Related Intelligence
Blog
Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future
Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which are expected to improve patient access while balancing financial healthcare sustainability and overall market […]
Read More
Blog
Japan Pricing Policy Reform 2024
Executive Summary The Central Social Insurance Medical Council, the key Japanese reimbursement policy panel known as Chuikyo, introduced the 2024 drug pricing reform in April 2024. Some key features of the reform plan include: The reform outlines a suite of measures aimed at driving innovation while also addressing drug lags (delay in manufacturers launching drugs in Japan […]
Read More
Webinars
HTA Vision—Implications Beyond the Rating
Available On Demand
A number of critical manufacturer activities are informed by understanding health technology assessment (HTA) agency behavior across geographies and therapeutic areas—from pipeline, business development and licensing to launch planning preparation through to lifecycle management strategy. Join Max Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access & Pricing Practice, as he hosts a lively […]
Watch Now